Pierre-Bénite, France
Pierre-Bénite, France

Time filter

Source Type

Patent
University Los Andes, Hospital Universitario San Ignacio and Hospices Civils De Lyon | Date: 2016-11-14

A computer-based method is herein disclosed, allowing to differentiate automatically between two tissues of interest: an extrinsic and an intrinsic tissue, from a plurality of images, obtaining a quantitative assessment of each of said tissues without requiring the intervention of an expert. Said method involves the definition of a differentiation region in images obtained from a medical imaging acquisition device using a parametric contour, after which differentiation and quantification are carried out based on the photometric characteristics of the different tissues observed in images, evaluating the local neighborhood of each voxel belonging to the differentiation region previously defined in the plurality of images. The disclosed method increases to a great extent precision in differentiation and quantification of tissues, while the shown percentage error is considered tolerable for diagnostic purposes.


Patent
University Los Andes, Hospital Universitario San Ignacio, Hospices Civils De Lyon, Mendoza Leon, Uriza Carrasco, Douek and Hernandez | Date: 2017-03-22

A computer-based method is herein disclosed, allowing to differentiate automatically between two tissues of interest: an extrinsic and an intrinsic tissue, from a plurality of images, obtaining a quantitative assessment of each of said tissues without requiring the intervention of an expert. Said method involves the definition of a differentiation region in images obtained from a medical imaging acquisition device using a parametric contour, after which differentiation and quantification are carried out based on the photometric characteristics of the different tissues observed in images, evaluating the local neighborhood of each voxel belonging to the differentiation region previously defined in the plurality of images. The disclosed method increases to a great extent precision in differentiation and quantification of tissues, while the shown percentage error is considered tolerable for diagnostic purposes.


Patent
University Claude Bernard Lyon 1, Hospices Civils De Lyon and University of Washington | Date: 2017-03-29

The present invention relates to the use of at least one biomarker for predicting the severity of a disease caused by the infection of an individual with an influenza virus, wherein said biomarker is selected in a group comprising (i) the alpha diversity value of the microbiome present in a respiratory sample of said individual and (ii) the microbiome profile of the said respiratory sample.


Patent
Hospices Civils De Lyon and University Claude Bernard Lyon 1 | Date: 2015-06-05

The invention relates to an in vitro process for determining the functional IL-17 pro-inflammatory dependent level (IPDL) of a biological sample, comprising the following steps:


The present invention relates to an in vitro method for determining the functional IL-17 pro-inflammatory dependent level (IPDL) of a biological sample, comprising the following steps: a) measuring the level of an inflammatory marker produced by IL-17-sensitive cells, incubated in the presence of a biological sample, b) measuring the level of said inflammatory marker produced by said cells incubated in the presence of a biological sample, in the presence of antibodies which neutralize the biological activity of IL-17, and c) determining the PIPDL value, which is the difference between the level of said inflammatory marker measured in step a) and the level of said inflammatory marker measured in step b).


Patent
International Drug Development Biotech, Hospices Civils De Lyon and French National Center for Scientific Research | Date: 2017-07-12

The presentdisclosure relates to a human CK8 antigen peptide, an antibody, or antibody fragment thereof, or a humanized antibody, specifically binding the peptide having the amino acid sequence of SEQ ID No. 29, a fragment of CK-8. Said molecules can be used use in the detection and/or treatment of tumors whose cells express CK8 protein, in particular the peptide of sequence according to SEQ ID No.29, on their surface.


Grant
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: PHC-15-2015 | Award Amount: 6.34M | Year: 2015

Stroke is the second leading cause of death in the world population. When not fatal, stroke often results in disability, due to motor and cognitive impairments, and secondary health problems affecting not only patients but also their families. Building on emerging preclinical and pilot clinical evidences, RESSTORE will focus on the clinical assessment of regenerative cell therapy to improve stroke recovery and patients quality of life. RESSTORE European multicentre randomised phase IIb will explore, for the first time, the efficacy (functional recovery) and safety of intravenous infusion of allogenic adipose tissue derived mesenchymal stem cells (ADMSCs) in 400 stroke patients. Therapeutic effects of ADMSCs will be assessed and monitored in patients using clinical rating scales, multimodal MRI and novel blood biomarkers. Additionally, the societal value and cost-effectiveness of ADMSCs-based regenerative therapy will be evaluated through health economics and predictive in silico simulations. Complementary ancillary animal studies will support the clinical trial by defining i) if the treatment response can be further enhanced by intensive rehabilitation, ii) the contribution of co-morbidities and iii) the mechanism(s) underlying the therapeutic effect. The European regenerative therapy capacities (France, Spain, Finland, United Kingdom and Czech Republic), developed in RESSTORE will cover the full value chain in the field (large scale GMP cell production, clinical testing, biomarkers discovery, understanding of the restoring mechanisms, modelling, biobanking, economic studies, exploitation and communication plan). RESSTORE will thus surely contribute, together with the workforce trained in the context of the programme, to improve its public and private (SME) competitiveness and increase the attractiveness of Europe as a reference location to develop and clinically assess new innovative therapeutic options for brain diseases.


Patent
French National Center for Scientific Research, University of Strasbourg, Hospices Civils De Lyon and University Claude Bernard Lyon 1 | Date: 2015-04-01

Dendronized metallic oxide nanoparticles, a process for preparing the same and their uses.


Grant
Agency: European Commission | Branch: FP7 | Program: BSG-SME | Phase: SME-2013-1 | Award Amount: 2.79M | Year: 2013

Interest in the use of naturally occurring human gut bacteria as pharmaceutical drugs has increased as knowledge about the human microbiota and its role in health and disease has advanced. The ELIMOX project proposes to develop a new drug from Oxalobacter formigenes, an anaerobic bacterium whose only carbon source is oxalate, for the treatment of primary hyperoxaluria (PH). PH is a rare and life-threatening disease, present at birth, characterised by high endogenous levels of oxalate that damage the kidney and cause renal failure. Enteric elimination of oxalate via the gut provide an alternative elimination pathway for the oxalate and treatment with pharmacological doses of O. formigenes would facilitate such enteric elimination. The treatment employs a new approach whereby bacterial breakdown of excessive oxalate occurs in the gut, inducing an alternative pathway for the oxalate, thereby protecting the kidneys from failure. The O. formigenes approach to treat PH is an ideal model for bacterial treatment of metabolic disease. The three SME participants will utilise the expertise of nine specialised research providers to increase the understanding of the characteristics of the sensitive, anaerobic and highly specialised O. formigenes, to implement the manufacturing process to obtain a clinically effective drug, to optimise drug delivery and to develop specialised analytical methods to monitor clinical effects following treatment. Technology advancements will be confirmed by clinical studies in PH patients and by mapping the presence of the bacteria before and after treatment with the O. formigenes drug. The ELIMOX project will advance current standards and methodology in i) manufacture of anaerobic bacteria for pharmaceutical use, ii) identification, quantification and tracking of microbes in the human gut and their impact on human microbiota during treatment, iii) optimisation of tools to monitor clinical effects during treatment with anaerobic bacteria.


Grant
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: PHC-22-2015 | Award Amount: 7.09M | Year: 2016

As the number of older people in Europe grows, increasing healthy life years is a priority. Cognitive decline, dementia (e.g. Alzheimers disease, AD), sleep disturbances and depression, all related to psychological distress and anxiety, are significant drivers of reduced quality of life in older adults. This project builds on evidence that lifestyle factors and meditation practice have the potential to downregulate these adverse factors and positively impact mental and neurological conditions including AD. Our main objectives are i) to improve early AD detection and understanding of physiopathological mechanisms; and to investigate ii) the impact of internal/external (e.g. genetic and lifestyle) determinants and iii) the effect and mechanisms of action of meditation training, on mental health and wellbeing in older people. This will be achieved by using pre-existing databases from European partners and conducting two randomized controlled trials (Studies 1 and 2B) and one observational study (2A). STUDY 1 will assess the short-term effects of an 8-week meditation intervention (versus cognitive training) in patients with subjective cognitive decline at risk for AD on behavioural measures including anxiety and wellbeing. STUDY 2A will assess senior expert meditators to identify neural signatures of different meditation practices on attention and emotion regulation tasks. STUDY 2B will assess long-term effects of an 18-month meditation intervention (versus an active control) on behavioural and biological markers of mental health and wellbeing in cognitively intact elderly. The cognitive and affective regulatory mechanisms underlying these effects will be investigated using the neural signatures identified in the expert meditators. High public health relevance is likely: the proposed intervention targets the most common mental and neurological conditions in the elderly and it can be scaled up within preventive programmes at a population level.

Loading Hospices Civils de Lyon collaborators
Loading Hospices Civils de Lyon collaborators